18 research outputs found
The effect of personality traits on file retrieval
File retrieval is important for Personal Information Management (PIM). If retrieval fails, people cannot re-use files that they created or other people shared with them. In this paper, we examined the effect of personality traits on retrieval success and efficiency in two studies. Study 1 (n = 60) examined the effect of the Big Five personality traits. Study 2 (n = 300) evaluated the effect of other personality traits that we hypothesized would improve retrieval: need for control, orderliness, memory, computer literacy, minimalism, stress resistance, sociability and empathy. None of the tests we conducted were significant, meaning that even if future effects are identified, they will most probably be weak. In contrast, significant effects on retrieval success and efficiency were previously found for factors such as: sharing method, file collection size, number of collaborators sharing the file, file versions, recency since last retrieval, folder depth and workload. Nevertheless, the null-results we report here are important because the failure to publish non-significant results can have a negative influence on re-search. Otherwise these effects may be repeatedly studied until significant results emerge and are published, possibly because of a type I error
Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen
A pivotal role is attributed to the estrogenreceptor
(ER) pathway in mediating the effect of estrogen
in breast cancer progression. Yet the precise mechanisms
of cancer development by estrogen remain poorly understood.
Advancing tumor categorization a step forward,
and identifying cellular gene fingerprints to accompany
histopathological assessment may provide targets for therapy
as well as vehicles for evaluating the response to
treatment. We report here that in breast carcinoma,
estrogen may induce tumor development by eliciting
protease-activated receptor-1 (PAR1) gene expression.
Induction of PAR1 was shown by electrophoretic mobility
shift assay, luciferase reporter gene driven by the hPar1
promoter, and chromatin-immunoprecipitation analyses.
Functional estrogen regulation of hPar1 in breast cancer
was demonstrated by an endothelial tube-forming network.
Notably, tissue-microarray analyses from an established
cohort of women diagnosed with invasive breast
carcinoma exhibited a significantly shorter disease-free
(P 0.006) and overall (P 0.02) survival of patients that
were positive for ER and PAR1, compared to ER-positive
but PAR1-negative patients. We propose that estrogen
transcriptionally regulates hPar1, culminating in an aggressive
gene imprint in breast cancer. While ER patients are
traditionally treated with hormone therapy, the presence
of PAR1 identifies a group of patients that requires
additional treatment, such as anti-PAR1 biological vehicles
or chemotherapy.—Salah, Z., Uziely, B., Jaber, M., Maoz,
M., Cohen, I., Hamburger, T., Maly, B., Peretz, T., B.-S,
R. Regulation of human protease-activated receptor 1
(hPar1) gene expression in breast cancer by estrogen
A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer
BACKGROUND: The incidence of breast cancer (BC) in Arab women is lower compared to the incidence in the Jewish population in Israel; still, it is the most common malignancy among Arab women. There is a steep rise in breast cancer incidence in the Arab population in Israel over the last 10 years that can be attributed to life style changes. But, the younger age of BC onset in Arab women compared with that of the Jewish population is suggestive of a genetic component in BC occurrence in that population. METHODS: We studied the family history of 31 women of Palestinian Arab (PA) origin affected with breast (n = 28), ovarian (n = 3) cancer. We used denaturing high performance liquid chromatography (DHPLC) to screen for mutations of BRCA1/2 in 4 women with a personal and family history highly suggestive of genetic predisposition. RESULTS: A novel BRCA1 mutation, E1373X in exon 12, was found in a patient affected with ovarian cancer. Four of her family members, 3 BC patients and a healthy individual were consequently also found to carry this mutation. Of the other 27 patients, which were screened for this specific mutation none was found to carry it. CONCLUSION: We found a novel BRCA1 mutation in a family of PA origin with a history highly compatible with BRCA1 phenotype. This mutation was not found in additional 30 PA women affected with BC or OC. Therefore full BRCA1/2 screening should be offered to patients with characteristic family history. The significance of the novel BRCA1 mutation we identified should be studied in larger population. However, it is likely that the E1373X mutation is not a founder frequent mutation in the PA population
Potential Refinement of Recurrence Score by pSTAT3 Status
The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population